Therapeutic management of premenstrual syndrome

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 17, 2010, Pages 2879-2889

  Freeman, Ellen W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Menstrual disorders; Oral contraceptives; PMS; Premenstrual syndrome; Serotonin reuptake inhibitors; Treatment

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BUSERELIN; BUSPIRONE; CALCIUM; CITALOPRAM; CLOMIPRAMINE; DANAZOL; DESIPRAMINE; DROSPIRENONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; GONADORELIN; LEUPRORELIN; LEVONORGESTREL; MAPROTILINE; MEDROXYPROGESTERONE ACETATE; NANDROLONE; PAROXETINE; PLACEBO; PROGESTERONE; PYRIDOXINE; SERTRALINE; SPIRONOLACTONE; UNINDEXED DRUG; VENLAFAXINE; VITAMIN D;

ACNE; BEHAVIOR DISORDER; BLOATING; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; COGNITIVE THERAPY; CONCENTRATION (PARAMETERS); DIARRHEA; DIZZINESS; DRUG MEGADOSE; DYSMENORRHEA; ESTROGEN THERAPY; FATIGUE; FLUID RETENTION; HEADACHE; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INSOMNIA; LETHARGY; LIBIDO; LUTEAL PHASE; MASTALGIA; MENORRHAGIA; MOOD DISORDER; NAUSEA; OVARIECTOMY; OVULATION INHIBITION; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SWELLING; TREATMENT RESPONSE; VITEX AGNUS CASTUS; VOICE CHANGE; WEIGHT GAIN;

CALCIUM, DIETARY; COGNITIVE THERAPY; CONTRACEPTIVES, ORAL, HORMONAL; DIETARY SUPPLEMENTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; PHYTOTHERAPY; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; VITEX;

EID: 78149457019     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.509344     Document Type: Review

References (108)

1. Brown WJ, Doran FM. Womens health: consumer views for planning local health promotion and health care priorities. Aust N Z J Public Health 1996;20:149-54
2. Corney RH, Stanton R. A survey of 658 women who report symptoms of premenstrual syndrome. J Psychosom Res 1991;35:471-82
3. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104:110-16
4. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32
5. Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000;13:287-304
6. Sternfeld B, Swindle R, Chawla A, et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002;99:1014-24
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 1994
8. Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008;33:291-301
9. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006;15:57-69
10. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 15 April 2000. Premenstrual syndrome. Obstet Gynecol 2000;95:1-9
11. Royal College of Obstetricians and Gynaecologists. Management of Premenstrual Syndrome. In: Clinical Green-Top Guideline No. 48. RCOG Press, London; 2007
12. Brown J, Orien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009;(2):CD001396
13. Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008;111:1175-82
14. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of remenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-34
15. Freeman EW, Rickels K, Sammel MD, et al. Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline. Arch Gen Psychiatry 2009;66:537-44
16. Altshuler LL, Cohen LS, Moline ML, et al. Expert consensus panel for depression in women. The expert consensus guideline series. Treatment of depression in women. Postgrad Med 2001;(Spec No):1-107
17. Freeman EW, Rickels K, Sondheimer SJ, et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004;161:343-51
18. Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 2004;66:707-13
19. Eriksson E, Ekman A, Sinclair S, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 2008;28:195-202
20. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66
21. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-44
22. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-29
23. Landen M, Nissbrandt H, Allgulander C, et al. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153-61
24. Steiner M, Ravindran AV, LeMelledo JM, et al. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry 2008;69:991-8
25. Freeman EW, Sondheimer SJ, Sammel MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005;66:769-73
26. Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 2006;26:198-202
27. Kornstein SG, Pearlstein TB, Fayyad R, et al. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 2006;67:1624-32
28. Ravindran LN, Woods SA, Steiner M, Ravindran AV. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health 2007;10:125-7
29. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417-33
30. Cohen LS, Soares CN, Lyster A, et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004;24:540-3
31. Freeman EW, Sondheimer SJ, Rickels K, Martin PG. A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome. J Clin Psychopharmacol 2004;24:351-3
32. Yonkers KA, Barnett LK, Carmody T, Rush AJ. Serial discontinuation of SSRI treatment for PMDD. Biol Psychiatry 1998;43:1S-133S
33. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332-5
34. Elks ML. Open trial of fluoxetine therapy for premenstrual syndrome. South Med J 1993;86:503-7
35. Zimmerman M, Thongy T. How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry 2007;68:1271-6
36. Quitkin FM, Stewart JW, McGrath PJ, et al. Loss of drug effects during continuation therapy. Am J Psychiatry 1993;150:562-5
37. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001;98:737-44
38. Cohen LS, Soares CN, Lyster A, et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004;24:540-3
39. Freeman EW, Rickels K, Arredondo F, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999;19:3-8
40. Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997;17:261-6
41. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76
42. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-7
43. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994;84:379-85
44. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990;47:270-5
45. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987;70:37-43
46. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993;50:467-73
47. Dennerstein L, Morse C, Burrows G, et al. Alprazolam in the treatment of premenstrual syndrome. In: Dennerstein L, Fraser I, editors, Hormones and behavior, Elsevier Science Publishing, New York, NY; 1986. p. 175
48. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 1989;1:777
49. Landen M, Eriksson O, Sundblad C, et al. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 2001;155:292-8
50. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-16
51. Weisz G, Knaapen L. Diagnosing and treating premenstrual syndrome in five western nations. Soc Sci Med 2009;68:1498-505
52. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993;37:195-202
53. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-66
54. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992;46:253-68
55. Andersch B. The effect of various oral contraceptive combinations on premenstrual symptoms. Int J Gynaecol Obstet 1982;20:463-9
56. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501
57. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21
58. Foidart JM. Added benefits of drospirenone for compliance. Climacteric 2005;8:28-34
59. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009;(2):CD006586
60. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6
61. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003;67:9-13
62. Freeman EW, Borisute H, Deal L, et al. A continuous-use regimen of levonorgestrel/ethinyl estradiol significantly alleviates cycle-related symptoms: results of a phase 3 study. Fertil Steril 2005;84:S25
63. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-19
64. Maddocks S, Hahn P, Moller F, Reid RL. A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am J Obstet Gynecol 1986;154:573-81
65. Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 1990;264:349-53
66. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2009;(2):CD003415
67. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988;67:159-66
68. Hussain SY, Massil JH, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992;6:57-64
69. Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994;84:779-86
70. Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without add-back therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004;111:585-93
71. Segebladh B, Borgstrom A, Nyberg S, et al. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 2009;201:139.e1-8
72. Di Carlo C, Palomba S, Tommaselli GA, et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001;75:380-4
73. Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. Br Med J (Clin Res Ed) 1986;292:1629-33
74. Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;2:730-2
75. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995;102:475-84
76. Kurshan N, Neill Epperson C. Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Womens Ment Health 2006;9:1-14
77. Usman SB, Indusekhar R, OBrien S. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008;22:251-60
78. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995;102:475-84
79. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004;19:2152-5
80. Andersch B, Hahn L, Andersson M, Isaksson B. Body water and weight in patients with premenstrual tension. Br J Obstet Gynaecol 1978;85:546-50
81. OBrien PM, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 1979;86:142-7
82. Vellacott ID, Shroff NE, Pearce MY, et al. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987;10:450-6
83. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995;74:803-8
84. Burnet RB, Radden HS, Easterbrook EG, McKinnon RA. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991;31:366-8
85. Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991;34:243-8
86. Watts JF, Butt WR, Logan Edwards R. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987;94:30-4
87. Sarno AP Jr, Miller EJ Jr, Lundblad EG. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet Gynecol 1987;70:33-6
88. Vigod SN, Frey BN, Soares CN, Steiner M. Approach to premenstrual dysphoria for the mental health practitioner. Psychiatr Clin North Am 2010;33:257-72
89. Fugh-Berman A, Kronenberg F. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol 2003;17:137-52
90. Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt) 2009;18:895-9
91. Tesch BJ. Herbs commonly used by women: an evidence-based review. Am J Obstet Gynecol 2003;188:S44-55
92. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009;16:e407-29
93. Bertone-Johnson ER, Chocano-Bedoya PO, Zagarins SE, et al. Dietary vitamin D intake, 25-hydroxyvitamin D(3) levels and premenstrual syndrome in a college-aged population. J Steroid Biochem Mol Biol 2010. [Epub ahead of print]
94. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 2009;105:158-61
95. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998;179:444-52
96. Ghanbari Z, Haghollahi F, Shariat M, et al. Effects of calcium supplement therapy in women with premenstrual syndrome. Taiwan J Obstet Gynecol 2009;48:124-9
97. Wyatt KM, Dimmock PW, Jones PW, Shaughn OBrien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999;318:1375-81
98. Webster DE, Lu J, Chen SN, et al. Activation of the mu-opiate receptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J Ethnopharmacol 2006;106:216-21
99. Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol 2010. [Epub ahead of print]
100. He Z, Chen R, Zhou Y, et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas 2009;63:99-103
101. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001;322:134-7
102. Canning S, Waterman M, Orsi N, et al. The efficacy of Hypericum perforatum (St Johns wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24:207-25
103. Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG 2000;107:870-6
104. Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control Clin Trials 1996;17:60-8
105. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health 2009;12:85-96
106. Busse JW, Montori VM, Krasnik C, et al. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 2009;78:6-15
107. Hunter MS, Ussher JM, Browne SJ, et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002;23:193-9
108. Rubinow DR, Schmidt PJ. Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Front Neuroendocrinol 2006;27:210-16